Injectsense's future plans for the sensor are to fine-tune its delivery tool and incorporate a microbattery into the sensor.
Digital health company Injectsense announced that it has successfully completed the first human implant and wireless IOP measurements using its ultraminiature implantable sensor, which has received FDA breakthrough designation.1 The implant procedure was performed during the IOP-Connect system study by Juan Mura, MD, of the Centro de la Vision in Santiago, Chile, according to a news release.
"From a physician's perspective, this is a major step toward understanding IOP fluctuations and providing more effective glaucoma treatment," said Mura in the release. "It's extremely exciting to have a direct path to an implantable sensor that will provide autonomous measurement 24/7."
Injectsense now plans on fine-tuning the delivery tool for the sensor and to incorporate the Injectpower SAS solid-state microbattery into the sensor. This microbattery will allow for autonomous and continuous measurement of IOP from inside the eye, according to the release. The final product platform will then use smart glasses work by patients for a few minutes each week in order to wirelessly recharge the sensor and uploaded sensor-stored data to a smart phone and cloud platform.1
"Although safety is the primary focus of this study, we are also informing our product design to meet the expectations of ophthalmologists across the globe," said Ariel Cao, President/CEO of Injectsense. "We expect these sensors to be easily delivered in the doctor's office."
In November 2023, Injectsense announced that it secured $9.4 million in funding with sister company Injectpower to bring the implantable device into production.2